- The US Food and Drug Administration (FDA) has expanded the indication for HPV 9-valent vaccine, recombinant (Gardasil-9) to include prevention of oropharyngeal and other cancers of head and neck caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
- The expanded indication approved under the FDA's accelerated approval program is based on the vaccine's efficacy in preventing HPV-related anogenital disease.
- HPV has been established as the causative agent for most oropharyngeal squamous cell cancers diagnosed in the United States.
- A study published in 2019 found that the frequency of oral HPV infections was lower among sexually active female adolescents who had received the quadrivalent vaccine than among unvaccinated individuals.
- The findings suggested that vaccination could lower the future risk for HPV-associated head and neck cancers.
- Individuals at risk for exposure to a new HPV infection from a new sex partner are most likely to benefit from HPV vaccination.
- Approval of the expanded indication is contingent on confirmatory data awaited from an ongoing phase 3 multicenter randomized trial in men ages 20-45 years.
For Prescribing Information, click here.